Comparative Pharmacokinetic Study between Metformin Alone and Combined with Orlistat in Healthy Mexican Volunteers

Noemí Santos-Caballero, Francisco Javier Flores-Murrieta

Landsteiner Scientific, S.A. de C.V., México, D.F., Mexico;.
Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, México, D.F., Mexico;.

DOI: 10.4236/pp.2012.33040                

Abstract

Traditional treatment of type 2 diabetes mellitus (T2DM) has focused on correcting hyperglycemia. However, T2DM is almost always accompanied by other conditions and risk factors that affect its morbidity and mortality. Obesity represents one of the main risk factors associated in the T2DM and a modest weight loss around 5% is linked with significant reduction in the blood glucose levels. The objective of this study was to compare the pharmacokinetic parameters between two formulations of metformin, alone or combined with orlistat, in healthy volunteers. A single-blinded, single dose, two-period, two-sequence, crossover, randomized and balanced study design with a 7-day washout period was performed in 26 Mexican volunteers. Plasma samples were collected over a 24-hour period after administration of 500 mg metformin alone or combined with 60 mg orlistat in each period. A validated high-performance liquid chromatography coupled with a ultraviolet detector was used to analyze metformin concentration in plasma. Bioequivalence between metformin alone and metformin combined with orlistat was determined when the ratio for the 90% confidence intervals (CI) of area under the curve (AUC_24h) and maximum concentration (C_max) of the two formulations were within 80% and 125%. In the current study, the mean ± standard deviation (SD) of C_max, AUC_24h and AUC_∞ of the formulation containing only metformin were 1.39 ± 0.44 μg/mL, 7.59 ± 3.17 μg h/mL and 8.48 ± 4.13 μg h/mL, respectively, while the mean ± SD of C_max, AUC_24h and AUC_∞ of the formulation containing metformin and orlistat were 1.38 ± 0.48 μg/mL, 7.80 ± 2.83 μg h/mL and 9.13 ± 4.29 μg h/mL, respectively. The parametric 90% CI for C_max and AUC_24h were 87.5-109.3 and 88.7-124.7, respectively. These results suggest that both formulations are bioequivalent and there is not pharmacokinetic interaction between metformin and orlistat.

Keywords

Metformin; Orlistat; Diabetes; Obesity; Bioequivalence; Pharmacokinetic

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	WORLD HEALTH ORGANIZATION, “MEDIA CENTRE, DIABETES, FACT SHEET N 312,” AUGUST 2011. HTTP://WWW.WHO.INT/MEDIACENTRE/FACTSHEETS/FS312/EN/INDEX.HTML
[2]	J. E. SHAW, R. A. SICREE AND P. Z. ZIMMET, “GLOBAL ESTIMATES OF THE PREVALENCE OF DIABETES FOR 2010 AND 2030,” DIABETES RESEARCH AND CLINICAL PRACTICE, VOL. 87, NO. 7, 2010, PP 4-14.
[3]	Secretaría de Salubridad y Asistencia, “Bases Técnicas del Acuerdo Nacional para la Salud Alimentaria, Estrategia Contra el Sobrepeso y la Obesidad,” 1st Edition, Subdirección de Comunicación Científica y Publicaciones del Instituto Nacional de Salud Pública, México, 2010.
[4]	S. Braun, K. Bitton-Worms and D. Leroith. “The Link between the Metabolic Syndrome and Cancer,” International Journal of Biological Sciences, Vol. 7, N0. 7, 2011, pp 1003-1015.
[5]	E. Kassi, P. Pervanidou, G. Kaltsas and G. Chrousos, “Metabolic Syndrome: Definitions and Controversies,” BMC Medicine, Vol. 9, 2011, p. 48.
[6]	R. J. Rodríguez-Kú, “Metabolicsyndrome and Cerebro- vascular Disease: Evidence in Their Treatment,” Revista de Neurología, Vol. 48, No. 5, 2009, pp. 255-260.
[7]	S. Mottillo, K. B. Filion, J. Genest, L. Joseph, L. Pilote, P. Poirier, S. Rinfret, E. L. Schiffrin and M. J. Eisenberg, “The Metabolic Syndrome and Cardiovascular Risk a Systematic Review and Meta-Analysis,” Journal of the American College of Cardiology, Vol. 56, No. 14, 2010, pp. 1113-1132. doi:10.1016/j.jacc.2010.05.034
[8]	D. C. Lau, “Diabetes and Weight Management,” Primary Care Diabetes, Suppl. 1, 2010, pp. S24-S30. doi:10.1016/S1751-9918(10)60006-X
[9]	L. B. Lorenz and R. A. Wild, “Polycystic Ovarian Syndrome: An Evidence-Based Approach to Evaluation and Management of Diabetes and Cardiovascular Risks for Today’s Clinician,” Clinical Obstetrics and Gynecology, Vol. 50, No. 1, 2007, pp. 226-243. doi:10.1097/GRF.0b013e31802f5197
[10]	R. P. Troiano, E. A. Frongillo Jr., J. Sobal and D. A. Levitsky, “The Relationship between Body Weight and Mortality: A Quantitative Analysis of Combined Information from Existing Studies,” International Journal of Obesity, Vol. 20, No. 1, 1996, pp. 63-75.
[11]	Y. D. Kim, K. G. Park, Y. S. Lee, Y. Y. Park, D. K. Kim, B. Nedumaran, W. G. Jang, W. J. Cho, J. Ha, I. K. Lee, C. H. Lee and H. S. Choi, “Metformin Inhibits Hepatic Gluconeogenesis through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP,” Diabetes, Vol. 57, No. 2, 2008, pp. 306-314. doi:10.2337/db07-0381
[12]	K. Niswender, “Diabetes and Obesity: Therapeutic Targeting and Risk Reduction—A Complex Interplay,” Diabetes, Obesity and Metabolism, Vol. 12, No. 4, 2010, pp. 267-287. doi:10.1111/j.1463-1326.2009.01175.x
[13]	C. J. Glueck, R. N. Fontaine, P. Wang, M. T. Subbiah, K. Weber, E. Illig, P. Streicher, L. Sieve-Smith, T. M. Tracy, J. E. Lang and P. McCullough, “Metformin Reduces Weight, Centripetal Obesity, Insulin, Leptin, and Low- Density Lipoprotein Cholesterol in Nondiabetic, Morbidly Obese Subjects with Body Mass Index Greater than 30,” Metabolism, Vol. 50, No. 7, 2001, pp. 856-861. doi:10.1053/meta.2001.24192
[14]	G. T. Tucker, C. Casey, P. J. Phillips, H. Connor, J. D. Ward and H. F. Woods, “Metformin Kinetics in Healthy Subjects and in Patients with Diabetes Mellitus,” British Journal of Clinical Pharmacology, Vol. 12, No. 2, 1981, pp. 235-246.
[15]	N. C. Sambol, J. Chiang, M. O’Conner, C. Y. Liu, E. T. Lin, A. M. Goodman, L. Z. Benet and J. H. Karam, “Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Subjects and Patients with Noninsulin-Dependent Diabetes Mellitus,” Journal of Clinical Pharmacology, Vol. 36, No. 11, 1996, pp. 1012-1021. doi:10.1177/009127009603601105
[16]	A. J. Scheen, “Clinical Pharmacokinetics of Metformin,” Clin Pharmacokinet, Vol. 30, No. 5, 1996, pp. 359-371. doi:10.2165/00003088-199630050-00003
[17]	D. Bhavesh, G. Chetan, K. M. Bhat and Shivprakash, “Estimation and Pharmacokinetics of Metformin in Human Volunteers,” Indian Journal of Pharmaceutical Education and Research, Vol. 41, No. 2, 2007, pp. 139- 139.
[18]	S. Al Hawari, E. AlGaai, A. Yusuf, A. Abdelgaleel and M. M. Hammami, “Bioequivalence Study of Two Metformin Formulations,” Arzneimittelforschung, Vol. 57, No. 4, 2007, pp. 192-195.
[19]	G. G. Graham, J. Punt, M. Arora, R. O. Day, M. P. Doogue, J. K. Duong, T. J. Furlong, J. R. Greenfield, L. C. Greenup, C. M. Kirkpatrick, J. E. Ray, P. Timmins and K. M. Williams, “Clinical Pharmacokinetics of Metformin,” Clinical Pharmacokinetics, Vol. 50, No. 2, 2011, pp. 81-98. doi:10.2165/11534750-000000000-00000
[20]	R. Padwal, S. K. Li and D. C. Lau, “Long-Term Pharmacotherapy for Overweight and Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,” International Journal of Obesity, Vol. 27, 2003, pp. 1437-1446. doi:10.1038/sj.ijo.0802475
[21]	R. S. Padwal and S. R. Majumdar, “Drug Treatments for Obesity: Orlistat, Sibutramine, and Rimonabant,” Lancet, Vol. 369, 2007, pp. 71-77. doi:10.1016/S0140-6736(07)60033-6
[22]	J. M. Miles, L. Leiter, P. Hollander, T. Wadden, J. W. Anderson, M. Doyle, J. Foreyt, L. Aronne and S. Klein, “Effect of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Treated with Metformin,” Diabetes Care, Vol. 25, No. 7, 2002, pp. 1123-1128. doi:10.2337/diacare.25.7.1123
[23]	R. Sari, M. K. Balci, F. Coban and G. Yazicioglu, “Comparison of the Effect of Orlistat vs Orlistat plus Metformin on Weight Loss and Insulin Resistance in Obese Women,” International Journal of Obesity, Vol. 28, No. 8, 2004, pp. 1059-1063. doi:10.1038/sj.ijo.0802707
[24]	E. Souri, H. Jalalizadeh, A. Kebriaee-Zadeh and B. Zadehvakili, “HPLC Analysis of Orlistat and Its Application to Drug Quality Control Studies,” Chemical & Pharmaceutical Bulletin, Vol. 55, No. 2, 2007, pp. 251- 254. doi:10.1248/cpb.55.251
[25]	S. C. Chow, H. Wang, “On Sample Size Calculation in Bioequivalence Trials,” Journal of Pharmacokinet Pharmacodyn, Vol. 28, No. 2, 2001, pp. 155-169. doi:10.1023/A:1011503032353
[26]	M. Rowland and T. N. Tozer, “Clinical Pharmacokinetics. Concepts and Applications,” 3rd Edition, Lea & Febiger, Philadelphia, London, 1995.
[27]	D. J. Schuirmann, “A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability,” Journal of Pharmacokinetics and Biopharmaceutics, Vol. 15, No. 6, 1987, pp. 657-680. doi:10.1007/BF01068419
[28]	S. S. Jain, S. J. Ramanand, J. B. Ramanand, P. B. Akat, M. H. Patwardhan and S. R. Joshi, “Evaluation of Efficacy and Safety of Orlistat in Obese Patients,” Indian Journal of Endocrinology and Metabolism, Vol. 15, No. 2, 2011, pp. 99-104. doi:10.4103/2230-8210.81938
[29]	R. A. DeFronzo and A. M. Goodman, “Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus. The Multicenter Metformin Study Group,” New England Journal of Medicine, Vol. 333, No. 9, 1995, pp. 541-549. doi:10.1056/NEJM199508313330902
[30]	R. Sari, M. K. Balci, E. Coban and G. Yazicioglu, “Comparison of the Effect of Orlistat vs Orlistat plus Metformin on Weight Loss and Insulin Resistance in Obese Women,” International Journal of Obesity, Vol. 28, No. 8, 2004, pp. 1059-1063. doi:10.1038/sj.ijo.0802707
[31]	J. M. Miles, L. Leiter, P. Hollander, T. Wadden, J. W. Anderson, M. Doyle, J. Foreyt, L. Aronne and S. Klein, “Effect of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Treated with Metformin,” Diabetes Care, Vol. 25, No. 7, 2002, pp. 1123-1128. doi:10.2337/diacare.25.7.1123